Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

March 10, 2021

AELIX has presented positive results from the clinical study AELIX-002 at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI)

Read more

March 10, 2021

Abstract of the oral presentation of the AELIX-002 study results at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI)

Read more

March 10, 2020

AELIX is partner in Horizon 2020 project MISTRAL

Read more
More

Testimonials